Read More

Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To BDCA2 Modulator Antibody Portfolio From Centessa Pharmaceuticals; Anaptys Will Pay Centessa A One-Time Upfront Cash Payment Of $7M

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory

ANAB

Read More

Multi-Million Dollar Cannabis Campus Sale To Help Canadian Pot Producer Pursue Organic Growth

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced on Monday that its wholly-owned subsidiary entered into an agreement with Future Farmco Canada Inc., a vertical farming company, for the sale and leaseback of its Ontario, Cananda-based property.

CRON